Endothelial monocyte activating polypeptide II: a mediator which activates host response

US6228837A · kind A · utility

Assignee

• The Trustees of Columbia University in the City of New York · US

Inventors

• David M. Stern · Great Neck, US
• Matthias Clauss · Indianapolis, US
• Janet Kao · New York, US
• Mark Kayton · New York, US
• Steven K. Libutti · North Potomac, US

Key dates

• Filing date: Oct 8, 1996
• Grant date: May 8, 2001
• Expiry date: Oct 8, 2016

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K38/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention provides a purified endothelial monocyte activating polypeptide (EMAP II). It further provides a method of obtaining purified endothelial monocyte activating polypeptide (EMAP II), a method of making antibodies to it and a method of detecting it. This invention also provides an effector cell activating protein which contains an amino acid sequence homologous to RIGRIVT and a method of detecting same. This invention also provides a method of treating a tumor in a subject by administering an effective dose of endothelial monocyte activating polypeptide (EMAP II).